Andere Sprachen Vistagen Therapeutics, Inc.

Aktien

A3EHA1

US92840H4002

VTGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.05.2024			% 5 Tage	% 1. Jan.
4,44 ^USD	-2,42 %		+1,60 %	-13,62 %

25.04.	Vistagen gibt positive Ergebnisse einer Phase-2A-Pilotstudie mit Ph15 zur Verbesserung psychomotorischer Beeinträchtigungen aufgrund geistiger Erschöpfung bekannt	CI
01.04.	Vistagen startet nach positiven Ergebnissen von PALISADE-2 die Phase-3-Studie PALISADE-3 mit Fasedienol zur akuten Behandlung von sozialer Angststörung	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference	07.05.
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25.04.
Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25.04.
Vistagen to Present at the 2024 Anxiety and Depression Association Conference	10.04.
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference	09.04.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01.04.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01.04.
Vistagen to Present at Stifel 2024 Virtual CNS Days	11.03.
Vistagen to Present at TD Cowen 44th Annual Health Care Conference	28.02.
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	13.02.
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update	13.02.
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024	06.02.
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	27.12.
Vistagen	27.12.
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	27.12.
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	27.12.
North American Morning Briefing : Futures Pause -2-	08.12.
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09.11.
Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $277.7M	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vistagen Therapeutics, Inc.

Aktien

A3EHA1

US92840H4002

VTGN

Andere Sprachen

Filter